DÄ internationalArchive37/2006Cardiotoxicity of Anthracyclines – an Unsolved Problem

Review article

Cardiotoxicity of Anthracyclines – an Unsolved Problem

Dtsch Arztebl 2006; 103(37): A-2393

Kruger, A; Wojnowski, L

For technical reasons, the English full text will be published approximately two weeks after the German print edition has been published.

1. Steinberg JS, Cohen AJ, Wasserman AG, Cohen P, Ross AM: Acute arrhythmogenicity of doxorubicin administration. Cancer 1987; 60: 1213–8. MEDLINE
2. Lefrak EA, Pitha J, Rosenheim S, Gottlieb JA: A clinicopathologic analysis of adriamycin cardiotoxicity. Cancer 1973; 32: 302–14. MEDLINE
3. Von Hoff DD, Layard MW, Basa P et al.: Risk factors for doxorubicin-induced congestive heart failure. Ann Intern Med 1979; 91: 710–7. MEDLINE
4. Swain SM, Whaley FS, Ewer MS: Congestive heart failure in patients treated with doxorubicin: a retrospective analysis of three trials. Cancer 2003; 97: 2869–79. MEDLINE
5. Speyer JL, Green MD, Zeleniuch-Jacquotte A et al.: ICRF-187 permits longer treatment with doxorubicin in women with breast cancer. J Clin Oncol 1992; 10: 117–27. MEDLINE
6. Tjeerdsma G, Meinardi MT, van der Graaf WTA et al.: Early detection of anthracycline induced cardiotoxicity in asymptomatic patients with normal left ventricular systolic function: autonomic versus echocardiographic variables. Heart 1999; 81: 419–23. MEDLINE
7. Jensen BV, Skovsgaard T, Nielsen SL: Functional monitoring of anthracycline cardiotoxicity: a prospective, blinded, long-term observational study of outcome in 120 patients. Ann Oncol 2002; 13: 699–709. MEDLINE
8. Steinherz LJ, Steinherz PG, Tan CT, Heller G, Murphy ML: Cardiac toxicity 4 to 20 years after completing anthracycline therapy. Jama 1991; 266: 1672–7. MEDLINE
9. Henderson IC, Allegra JC, Woodcock T et al.: Randomized clinical trial comparing mitoxantrone with doxorubicin in previously treated patients with metastatic breast cancer. J Clin Oncol 1989; 7: 560–71. MEDLINE
10. Wojnowski L, Kulle B, Schirmer M et al.: NAD(P)H oxidase and multidrug resistance protein genetic polymorphisms are associated with doxorubicin-induced cardiotoxicity. Circulation 2005; 112: 3754–62. MEDLINE
11. Zucchi R, Danesi R: Cardiac toxicity of antineoplastic anthracyclines. Curr Med Chem Anti-Canc Agents 2003; 3: 151–71. MEDLINE
12. Minotti G, Menna P, Salvatorelli E, Cairo G, Gianni L: Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity. Pharmacol Rev 2004; 56: 185–229. MEDLINE
13. Wouters KA, Kremer LC, Miller TL, Herman EH, Lipshultz SE: Protecting against anthracycline-induced myocardial damage: a review of the most promising strategies. Br J Haematol 2005; 131: 561–78. MEDLINE
14. Iarussi D, Indolfi P, Casale F, Martino V, Di Tullio MT, Calabro R: Anthracycline-induced cardiotoxicity in children with cancer: strategies for prevention and management. Paediatr Drugs 2005; 7: 67–76. MEDLINE
15. Legha SS, Benjamin RS, Mackay B et al.: Reduction of doxorubicin cardiotoxicity by prolonged continuous intravenous infusion. Ann Intern Med 1982; 96: 133–9. MEDLINE
16. Shapira J, Gotfried M, Lishner M, Ravid M:. Reduced cardiotoxicity of doxorubicin by a 6-hour infusion regimen. A prospective randomized evaluation. Cancer 1990; 65: 870–3. MEDLINE
17. Danesi R, Fogli S, Gennari A, Conte P, Del Tacca M: Pharmacokinetic-pharmacodynamic relationships of the anthracycline anticancer drugs. Clin Pharmacokinet 2002; 41: 431–44. MEDLINE
18. Cirillo R, Sacco G, Venturella S, Brightwell J, Giachetti A, Manzini S: Comparison of doxorubicin- and MEN 10755-induced long-term progressive cardiotoxicity in the rat. J Cardiovasc Pharmacol 2000; 35: 100–8. MEDLINE
19. Bos AM, de Vries EG, Dombernovsky P et al.: Pharmacokinetics of MEN-10755, a novel anthracycline disaccharide analogue, in two phase I studies in adults with advanced solid tumours. Cancer Chemother Pharmacol 2001; 48: 361–9. MEDLINE
20. Schrijvers D, Bos AM, Dyck J et al.: Phase I study of MEN-10755, a new anthracycline in patients with solid tumours: a report from the European Organization for Research and Treatment of Cancer, Early Clinical Studies Group. Ann Oncol 2002; 13: 385–91. MEDLINE
21. Singal PK, Iliskovic N, Li T, Kumar D: Adriamycin cardiomyopathy: pathophysiology and prevention. Faseb J 1997; 11: 931–6. MEDLINE
22. Singal PK, Li T, Kumar D, Danelisen I, Iliskovic N: Adriamycin-induced heart failure: mechanism and modulation. Mol Cell Biochem 2000; 207: 77–86. MEDLINE
23. van Dalen EC, Caron HN, Dickinson HO, Kremer LC: Cardioprotective interventions for cancer patients receiving anthracyclines. Cochrane Database Syst Rev 2005: CD003917. MEDLINE
24. Cvetkovic RS, Scott LJ:. Dexrazoxane: a review of its use for cardioprotection during anthracycline chemotherapy. Drugs 2005; 65: 1005–24. MEDLINE
Literatur Internet
e1.Kremer LC, van Dalen EC, Offringa M, Ottenkamp J, Voute PA: Anthracycline-induced clinical heart failure in a cohort of 607 children: long-term follow-up study. J Clin Oncol 2001; 19: 191–6. MEDLINE
e2.Green DM, Grigoriev YA, Nan B et al.: Congestive heart failure after treatment for Wilms' tumor: a report from the National Wilms' Tumor Study group. J Clin Oncol 2001; 19: 1926–34. MEDLINE
e3.Lipshultz SE, Colan SD, Gelber RD, Perez-Atayde AR, Sallan SE, Sanders SP: Late cardiac effects of doxorubicin therapy for acute lymphoblastic leukemia in childhood. N Engl J Med 1991; 324: 808–15. MEDLINE
e4.Pinkel D, Camitta B, Kun L, Howarth C, Tang T: Doxorubicin cardiomyopathy in children with left-sided Wilms tumor. Med Pediatr Oncol 1982; 10: 483–8. MEDLINE
e5.Grenier MA, Lipshultz SE: Epidemiology of anthracycline cardiotoxicity in children and adults. Semin Oncol 1998; 25: 72–85. MEDLINE
e6.Lipshultz SE, Lipsitz SR, Sallan SE et al.: Long-Term enalapril therapy for left ventricular dysfunction in doxorubicin-treated survivors of childhood cancer. J Clin Oncol 2002; 20: 4517–22. MEDLINE
e7.Forrest GL, Gonzalez B, Tseng W, Li X, Mann J: Human carbonyl reductase overexpression in the heart advances the development of doxorubicin-induced cardiotoxicity in transgenic mice. Cancer Res 2000; 60: 5158–64. MEDLINE
e8.Olson LE, Bedja D, Alvey SJ, Cardounel AJ, Gabrielson KL, Reeves RH: Protection from doxorubicin-induced cardiac toxicity in mice with a null allele of carbonyl reductase 1. Cancer Res 2003; 63: 6602–6. MEDLINE
e9.Gewirtz DA: A critical evaluation of the mechanisms of action proposed for the antitumor effects of the anthracycline antibiotics adriamycin and daunorubicin. Biochem Pharmacol 1999; 57: 727–41. MEDLINE
e10.Olson RD, Mushlin PS: Doxorubicin cardiotoxicity: analysis of prevailing hypotheses. Faseb J 1990; 4: 3076–86. MEDLINE
e11.Mordente A, Meucci E, Martorana GE, Giardina B, Minotti G: Human heart cytosolic reductases and anthracycline cardiotoxicity. IUBMB Life 2001; 52: 83–8. MEDLINE
e12.Bleyer WA: The impact of childhood cancer on the United States and the world. CA Cancer J Clin 1990; 40: 355–67. MEDLINE
e13.Hortobagyi GN: Anthracyclines in the treatment of cancer. An overview. Drugs 1997;54 (Suppl.) 4: 1–7. MEDLINE
e14.Berrak SG, Ewer MS, Jaffe N et al.: Doxorubicin cardiotoxicity in children: reduced incidence of cardiac dysfunction associated with continuous-infusion schedules. Oncol Rep 2001; 8: 611–4. MEDLINE
e15.Lipshultz SE, Giantris AL, Lipsitz SR et al.: Doxorubicin Administration by Continuous Infusion Is Not Cardioprotective: The Dana-Farber 91-01 Acute Lymphoblastic Leukemia Protocol. J Clin Oncol 2002; 20: 1677–82 MEDLINE .
e16.Gupta M, Steinherz PG, Cheung NK, Steinherz L: Late cardiotoxicity after bolus versus infusion anthracycline therapy for childhood cancers. Med Pediatr Oncol 2003; 40: 343–7. MEDLINE
e17.Levitt GA, Dorup I, Sorensen K, Sullivan I: Does anthracycline administration by infusion in children affect late cardiotoxicity? Br J Haematol 2004;124:463–8 MEDLINE .
e18.Gabizon A, Shmeeda H, Barenholz Y: Pharmacokinetics of pegylated liposomal Doxorubicin: review of animal and human studies. Clin Pharmacokinet 2003; 42: 419–36. MEDLINE
e19.Drummond DC, Meyer O, Hong K, Kirpotin DB, Papahadjopoulos D: Optimizing liposomes for delivery of chemotherapeutic agents to solid tumors. Pharmacol Rev 1999; 51: 691–743. MEDLINE
e20.Ryberg M, Nielsen D, Skovsgaard T, Hansen J, Jensen BV, Dombernowsky P: Epirubicin cardiotoxicity: an analysis of 469 patients with metastatic breast cancer. J Clin Oncol 1998; 16: 3502–8. MEDLINE
e21.Borchmann P, Hubel K, Schnell R, Engert A: Idarubicin: a brief overview on pharmacology and clinical use. Int J Clin Pharmacol Ther 1997; 35: 80–3. MEDLINE
e22.Anderlini P, Benjamin RS, Wong FC et al.: Idarubicin cardiotoxicity: a retrospective study in acute myeloid leukemia and myelodysplasia. J Clin Oncol 1995; 13: 2827–34. MEDLINE
e23.Cottin Y, Touzery C, Dalloz F et al.: Comparison of epirubicin and doxorubicin cardiotoxicity induced by low doses: evolution of the diastolic and systolic parameters studied by radionuclide angiography. Clin Cardiol 1998; 21: 665–70. MEDLINE
e24.Stohr W, Paulides M, Brecht I et al.: Comparison of epirubicin and doxorubicin cardiotoxicity in children and adolescents treated within the German Cooperative Soft Tissue Sarcoma Study (CWS). J Cancer Res Clin Oncol 2006; 132: 35–40. MEDLINE
e25.Burton C, Smith P, Vaughan-Hudson G et al.: Comparison of CHOP versus CIOP in good prognosis younger patients with histologically aggressive non-Hodgkin lymphoma. Br J Haematol 2005; 130: 536–41 MEDLINE .
e26.Lahtinen R, Kuikka J, Nousiainen T, Uusitupa M, Lansimies E: Cardiotoxicity of epirubicin and doxorubicin: a double-blind randomized study. Eur J Haematol 1991; 46: 301–5. MEDLINE
e27.Zinzani PL, Martelli M, Storti S et al.: Phase III comparative trial using CHOP vs CIOP in the treatment of advanced intermediate-grade non-Hodgkin's lymphoma. Leuk Lymphoma 1995; 19: 329–35. MEDLINE
e28.Wong BK, DeFeo-Jones D, Jones RE et al.: PSA-specific and non-PSA-specific conversion of a PSA-targeted peptide conjugate of doxorubicin to its active metabolites. Drug Metab Dispos 2001; 29: 313–8. MEDLINE
e29.DiPaola RS, Rinehart J, Nemunaitis J et al.: Characterization of a novel prostate-specific antigen-activated peptide-doxorubicin conjugate in patients with prostate cancer. J Clin Oncol 2002; 20: 1874–9. MEDLINE
e30.Broker LE, Giaccone G: The role of new agents in the treatment of non-small cell lung cancer. Eur J Cancer 2002; 38: 2347–61. MEDLINE
e31.Sacco G, Bigioni M, Evangelista S, Goso C, Manzini S, Maggi CA: Cardioprotective effects of zofenopril, a new angiotensin-converting enzyme inhibitor, on doxorubicin-induced cardiotoxicity in the rat. Eur J Pharmacol 2001; 414: 71–8. MEDLINE
e32.Santos JM, Luna Filho B, Simoes MJ, et al.: Effect of enalaprilat on cardiotoxicity induced by doxorubicin. Arq Bras Cardiol 1996; 67: 237–41. MEDLINE
e33.Okumura K, Jin D, Takai S, Miyazaki M: Beneficial effects of angiotensin-converting enzyme inhibition in adriamycin-induced cardiomyopathy in hamsters. Jpn J Pharmacol 2002; 88: 183–8. MEDLINE
e34.Boucek RJ, Jr., Steele A, Miracle A, Atkinson J: Effects of angiotensin-converting enzyme inhibitor on delayed-onset doxorubicin-induced cardiotoxicity. Cardiovasc Toxicol 2003; 3: 319–29. MEDLINE
e35.Vaynblat M, Shah HR, Bhaskaran D et al.: Simultaneous angiotensin converting enzyme inhibition moderates ventricular dysfunction caused by doxorubicin. Eur J Heart Fail 2002; 4: 583–6. MEDLINE
e36.Fujita N, Hiroe M, Ohta Y, Horie T, Hosoda S: Chronic effects of metoprolol on myocardial beta-adrenergic receptors in doxorubicin-induced cardiac damage in rats. J Cardiovasc Pharmacol 1991; 17: 656–61. MEDLINE
e37.Matsui H, Morishima I, Numaguchi Y, Toki Y, Okumura K, Hayakawa T: Protective effects of carvedilol against doxorubicin-induced cardiomyopathy in rats. Life Sci 1999; 65: 1265–74. MEDLINE
e38.Santos DL, Moreno AJ, Leino RL, Froberg MK, Wallace KB: Carvedilol protects against doxorubicin-induced mitochondrial cardiomyopathy. Toxicol Appl Pharmacol 2002; 185: 218–27. MEDLINE
e39.Thomas L, Bellmont S, Christen MO, La Roche B, Monassier L: Cardiovascular and survival effects of sympatho-inhibitors in adriamycin-induced cardiomyopathy in rats. Fundam Clin Pharmacol 2004; 18: 649–55. MEDLINE
e40.Oliveira PJ, Bjork JA, Santos MS et al.: Carvedilol-mediated antioxidant protection against doxorubicin-induced cardiac mitochondrial toxicity. Toxicol Appl Pharmacol 2004; 200: 159–68. MEDLINE
e41.Seymour L, Bramwell V, Moran LA: Use of dexrazoxan as a cardioprotectant in patients receiving doxorubicin or epirubicin chemotherapy for the treatment of cancer: the Provincial Systemic Treatment Disease Site Group. Cancer Prev Control 1999; 3: 145–59. MEDLINE